Department of Neurology, Mayo Clinic, Rochester, MN, USA; Department of Neurology, Rambam Medical Center, Haifa, Israel.
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Mayo Clin Proc. 2023 Apr;98(4):522-532. doi: 10.1016/j.mayocp.2022.11.020. Epub 2023 Feb 11.
To demonstrate early aging in patients with lamin A/C (LMNA) gene mutations after hypothesizing that they have a biological age older than chronological age, as such a finding impacts care.
We applied a previously trained convolutional neural network model to predict biological age by electrocardiogram (ECG) [Artificial Intelligence (AI)-ECG age] to LMNA patients evaluated by multiple ECGs from January 1, 2003, to December 31, 2019. The age gap was the difference between chronological age and AI-ECG age. Findings were compared with age-/sex-matched controls.
Thirty-one LMNA patients who had a total of 271 ECGs were studied. The median age at symptom onset was 22 years (range, <1-53 years; n=23 patients); eight patients were asymptomatic family members carrying the LMNA mutation. Cardiac involvement was detected by ECG and echocardiogram in 16 patients and consisted of ventricular arrhythmias (13), atrial fibrillation (12), and cardiomyopathy (6). Four patients required cardiac transplantation. Fourteen patients had neurological manifestations, mainly muscular dystrophy. LMNA mutation carriers, including asymptomatic carriers, were 16 years older by AI-ECG than non-LMNA carriers, suggesting accelerated biological age. Most LMNA patients had an age gap of more than 10 years, compared with controls (P<.001). Consecutive AI-ECG analysis showed accelerated aging in the LMNA group compared with controls (P<.0001). There were no significant differences in age-gap among LMNA patients based on phenotype.
AI-ECG predicted that LMNA patients have a biological age older than chronological age and accelerated aging even in the absence of cardiac abnormalities by traditional methods. Such a finding could translate into early medical intervention and serve as a disease biomarker.
通过假设携带 lamin A/C(LMNA)基因突变的患者具有比实际年龄更大的生物年龄,从而证明他们存在早衰现象,因为这一发现会影响到患者的护理。
我们应用之前训练好的卷积神经网络模型,通过心电图(ECG)预测生物年龄(AI-ECG 年龄),并对 2003 年 1 月 1 日至 2019 年 12 月 31 日期间接受多次 ECG 检查的 LMNA 患者进行评估。年龄差距为实际年龄与 AI-ECG 年龄之间的差值。研究结果与年龄和性别匹配的对照组进行了比较。
研究共纳入 31 例 LMNA 患者,共进行了 271 次 ECG 检查。症状发作的中位年龄为 22 岁(范围,<1-53 岁;23 例患者);8 例无症状的携带 LMNA 基因突变的家族成员。16 例患者通过心电图和超声心动图检测到心脏受累,包括室性心律失常(13 例)、心房颤动(12 例)和心肌病(6 例)。4 例患者需要进行心脏移植。14 例患者有神经表现,主要为肌肉萎缩症。AI-ECG 显示,LMNA 基因突变携带者(包括无症状携带者)比非 LMNA 携带者的生物年龄大 16 岁,提示存在加速的生物衰老。与对照组相比,大多数 LMNA 患者的年龄差距超过 10 岁(P<.001)。连续的 AI-ECG 分析显示,与对照组相比,LMNA 组的老化速度加快(P<.0001)。根据表型,LMNA 患者的年龄差距没有显著差异。
AI-ECG 预测 LMNA 患者的生物年龄大于实际年龄,即使通过传统方法未发现心脏异常,也存在加速衰老现象。这一发现可以转化为早期的医学干预,并作为疾病的生物标志物。